Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Read more about Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Read more about Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Read more about Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
Solid organ transplant rejection associated with immune-checkpoint inhibitors. Read more about Solid organ transplant rejection associated with immune-checkpoint inhibitors.
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Read more about Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Read more about Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
Reply to Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use? Read more about Reply to Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use?
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Read more about Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Read more about Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
Maintenance lenalidomide in primary CNS lymphoma. Read more about Maintenance lenalidomide in primary CNS lymphoma.
